Nasdaq: PRLD

Prelude Therapeutics Inc (PRLD)

Prelude Therapeutics Inc is a public company that reports to the U.S. Securities and Exchange Commission and trades on Nasdaq under the ticker PRLD. Bright Analyst brings its financial statements, SEC filings, stock performance, news and peer comparisons together in one place, with AI analysis throughout.

Key facts

Ticker symbol
PRLD
Exchange
Nasdaq
SEC CIK
1678660
Official filings
SEC EDGAR

Research PRLD

  • Profile — Business description, headquarters, subsidiaries and corporate identifiers.
  • Financials — Income statement, balance sheet and cash flow from 10-K and 10-Q filings.
  • SEC Filings — Every 10-K, 10-Q and 8-K, readable inline with AI analysis.
  • Stock Analysis — Price chart, returns, technical indicators and related companies.
  • News — Latest headlines and press coverage.
  • Material Contracts — Material agreements filed as exhibits to SEC reports.
  • Benchmark — Stock performance against the S&P 500, Nasdaq-100 and Dow (through SPY, QQQ and DIA) and economic indicators.
  • Peer Comparison — Side-by-side financial ratios against industry peers.

Frequently asked questions

What is Prelude Therapeutics Inc's stock ticker?

Prelude Therapeutics Inc trades under the ticker symbol PRLD on Nasdaq. Its SEC Central Index Key (CIK) is 1678660.

Where can I read Prelude Therapeutics Inc's SEC filings?

The PRLD SEC Filings page lists the 10-K annual reports, 10-Q quarterly reports and 8-K current reports Prelude Therapeutics Inc has filed, with AI analysis. The original documents are also on SEC EDGAR.

How can I analyze PRLD's financial statements?

The PRLD Financials page shows Prelude Therapeutics Inc's income statement, balance sheet and cash flow statement, annual and quarterly, taken from its XBRL filings, with an AI analysis of each statement.

How does PRLD compare with its peers and the market?

The PRLD Peer Comparison page lines Prelude Therapeutics Inc up against industry peers on valuation, growth and profitability ratios, and the Benchmark page compares its stock with the S&P 500, the Nasdaq-100 and the Dow.

For information only — not investment advice.